569 related articles for article (PubMed ID: 30423449)
1. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy.
Blumchen K; Trendelenburg V; Ahrens F; Gruebl A; Hamelmann E; Hansen G; Heinzmann A; Nemat K; Holzhauser T; Roeder M; Rosenfeld L; Hartmann O; Niggemann B; Beyer K
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):479-491.e10. PubMed ID: 30423449
[TBL] [Abstract][Full Text] [Related]
2. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
3. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
4. Parent and child perception of quality of life in a randomized controlled peanut oral immunotherapy trial.
Reier-Nilsen T; Carlsen KCL; Michelsen MM; Drottning S; Carlsen KH; Zhang C; Borres MP; Håland G
Pediatr Allergy Immunol; 2019 Sep; 30(6):638-645. PubMed ID: 31013372
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
6. Oral peanut immunotherapy in children with peanut anaphylaxis.
Blumchen K; Ulbricht H; Staden U; Dobberstein K; Beschorner J; de Oliveira LC; Shreffler WG; Sampson HA; Niggemann B; Wahn U; Beyer K
J Allergy Clin Immunol; 2010 Jul; 126(1):83-91.e1. PubMed ID: 20542324
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
[TBL] [Abstract][Full Text] [Related]
8. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response.
Varshney P; Jones SM; Scurlock AM; Perry TT; Kemper A; Steele P; Hiegel A; Kamilaris J; Carlisle S; Yue X; Kulis M; Pons L; Vickery B; Burks AW
J Allergy Clin Immunol; 2011 Mar; 127(3):654-60. PubMed ID: 21377034
[TBL] [Abstract][Full Text] [Related]
10. Peanut Oral Immunotherapy With or Without H
Chu DK; Freitag T; Marrin A; Walker TD; Avilla E; Freitag A; Spill P; Foster GA; Thabane L; Jordana M; Waserman S
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2386-2394. PubMed ID: 35643280
[TBL] [Abstract][Full Text] [Related]
11. High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small Children Oral Immunotherapy (SmaChO) Randomized Controlled Trial.
Uhl C; Klevebro S; Sverremark-Ekström E; Tedner SG; Brandström J; Papageorgiou C; Melén E; Konradsen JR; Nilsson C; Asarnoj A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1297-1305. PubMed ID: 38428524
[TBL] [Abstract][Full Text] [Related]
12. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial: a critical appraisal.
Marrs T; Flohr C; Perkin MR
Br J Dermatol; 2015 Nov; 173(5):1125-9. PubMed ID: 26769642
[TBL] [Abstract][Full Text] [Related]
13. Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study).
Chebar Lozinsky A; Loke P; Orsini F; O'Sullivan M; L Prescott S; Gold MS; Quinn P; DunnGalvin A; Lk Tang M;
BMJ Open; 2020 Sep; 10(9):e035871. PubMed ID: 32912942
[TBL] [Abstract][Full Text] [Related]
14. Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy.
Nagakura KI; Sato S; Yanagida N; Nishino M; Asaumi T; Ogura K; Ebisawa M
Int Arch Allergy Immunol; 2018; 175(3):181-188. PubMed ID: 29339650
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of desensitizing children highly allergic to peanut by high-dose oral immunotherapy.
Reier-Nilsen T; Michelsen MM; Lødrup Carlsen KC; Carlsen KH; Mowinckel P; Nygaard UC; Namork E; Borres MP; Håland G
Allergy; 2019 Feb; 74(2):337-348. PubMed ID: 30225844
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab.
Yee CSK; Albuhairi S; Noh E; El-Khoury K; Rezaei S; Abdel-Gadir A; Umetsu DT; Burke-Roberts E; LeBovidge J; Schneider L; Rachid R
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):451-461.e7. PubMed ID: 30267889
[TBL] [Abstract][Full Text] [Related]
17. AR101 Oral Immunotherapy for Peanut Allergy.
; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.
Bird JA; Spergel JM; Jones SM; Rachid R; Assa'ad AH; Wang J; Leonard SA; Laubach SS; Kim EH; Vickery BP; Davis BP; Heimall J; Cianferoni A; MacGinnitie AJ; Crestani E; Burks AW;
J Allergy Clin Immunol Pract; 2018; 6(2):476-485.e3. PubMed ID: 29092786
[TBL] [Abstract][Full Text] [Related]
19. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.
Anagnostou K; Islam S; King Y; Foley L; Pasea L; Bond S; Palmer C; Deighton J; Ewan P; Clark A
Lancet; 2014 Apr; 383(9925):1297-1304. PubMed ID: 24485709
[TBL] [Abstract][Full Text] [Related]
20. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
